37 results about "Apoferritins" patented technology

The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T^reg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.

In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed

The invention discloses protein-medicament-carrying PLGA composite microspheres and a preparation method thereof. According to the invention, an improved multiple emulsion-solvent evaporation method is adopted. On the basis of a multiple emulsion method, a principle that sodium alginate and calcium ions are subjected to chelating and form sustained-release gel is adopted; PLGA is adopted as a microsphere carrier; lyophilized injection-use recombinant human interferon-alpha, bovine serum albumin and the like are adopted as encapsulation objects; and the medicament-carrying microspheres are prepared. The microspheres are advantaged in round appearance, and uniform particle size distribution. An average particle size distribution is 70 micrometers, a medicament-carrying rate is above 0.6%, an encapsulation rate reaches approximately 50%, and an in-vitro medicament releasing performance satisfies the characteristic of prolonged-action preparations.

The invention provides a microneedle array for rapid transdermal delivery of protein drugs and a preparation method of the microneedle array, and belongs to the technical field of biomedicine. The structure of the microneedle array comprises a microneedle array substrate and a drug-loaded release layer deposited on the surface of a microneedle, and the drug-loaded release layer consists of a layer-by-layer self-assembled film formed by electrostatic interaction of the protein drugs and anionic polyelectrolyte. The microneedle array prepared by the method is simple and convenient to use, the application time is short and is only 10 seconds to 1 minutes, the microneedle array is taken away after application, self-administration of a patient is facilitated, the microneedle array has the advantages of being minimally invasive and painless, and compliance of the patient can be improved. The drugs are released quickly, and pharmacokinetics and pharmacodynamics equivalent to those of common subcutaneous injection can be obtained.

The invention discloses TGase-activating protease inhibitor (TAPI) producing engineering bacteria and a construction method thereof and belongs to the field of genetic engineering. In the invention, the complete gene sequence of TAPI in Streptomyceshygroscopicus is obtained for the first time by a molecular biological means, a recombinant plasmid pET22b(+)-TAPI is constructed according to the obtained sequence, the TAPI is expressed in Escherichia coli, and when the bacteria are used for producing TAPI, the yield can reach 10mg/L. The method has the advantages of simple process, high product yield and the like, and a safe, mild and green novel protein surfactant is developed; and the target protein produced by the strain can be secreted outside cells directly, so it is easy to separate and purify the target protein. The invention provides a reference and basis for the genetic expression of protein surfactants and exploits a new direction for the development of the protein surfactants.

The invention discloses a serum-free culture medium for culturing Vero cells and a preparation method thereof, the serum-free culture medium comprises a basic culture medium, the basic culture medium comprises glucose and glutamine, and the serum-free culture medium also comprises a main addition factor and a secondary addition factor, the main addition factors comprise proteins, hormones, growth factors, adherence promoting factors, trace elements and vitamins, and the secondary addition factors comprise a reducing agent, a trypsin inhibitor and a shear force protective agent. According to the culture medium, the Vero cells are cultured through the culture medium, normal growth of the Vero cells can be maintained, the amplification efficiency of the Vero cells can be improved, research, development and production of new coronavirus vaccines can be accelerated, the culture medium is clear in chemical component, free of serum and low in cost, biological safety risks caused by using serum are avoided, and the culture medium is suitable for popularization and application. The stability of a biological product production process and finished product quality is favorably improved.

The invention discloses medical nutrition powder for patients suffering from nephropathy without dialysis, and a preparation method of the medical nutrition powder, and relates to the technical fieldof medical foods. The medical nutrition powder for patients suffering from nephropathy without dialysis comprises the following components in parts by weight of 52.5-420 parts of protein type substances, 87-696 parts of fat type substances, 263.5-2108 parts of carbohydrate, 7.95-63.6 parts of composite mineral substances, 4.17-33.36 parts of complex vitamins, 0.4-3.2 parts of taurine, 0.5-4 partsof mono and diglycerides of fatty acids, 0.09-0.7 part of nucleotide, 0.06-0.48 part of L-carnitine, 9-72 parts of composite thickening agents, 1-8 parts of vanilla essence and 0.28-2.2 parts of aspartame, wherein the carbohydrate contains 194.5-1556 parts of maltodextrin, 15-120 parts of inulin and 5-40 parts of crystallization levulose. The medical nutrition powder disclosed by the invention adopts a low-protein formula, besides, the used protein is high-quality protein, whey protein contributes to intestinal tract absorption and has the effect of resisting oxidation, and soy protein isolatecan retard the descending level of glomerular filtration rate and retard the disease process of chronic nephropathy patients.

The present invention relates to a novel peptide extracted from guava (Psidium guajava) seeds, that provides bactericide activity, Preferentially against Gram-negative bacteria which are known to cause urinary, hospital, and intestinal tract infections (Proteus sp. And Klebsiella sp.). The peptide, that has the amino acid sequence RESPSSRMEC YEQAERYGYG GYGGGRYGGG YGSGRGQPVG QGVERSHDDN RNQPR, belongs to the class of glycine rich proteins and has approximately 5 kDa of molecular weight. The invention also relates to antibiotic compositions for human, veterinary and plant treatments. Alternatively, the peptide, or a functionally similar derivative, subjects of the present invention, can be used for transforming organisms aiming pathogen resistance, other adaptive advantages, as well as various properties, specially for plants and animals.

The invention provides a protein expression method. A serum-free animal-origin-free culture medium is used, a basic culture medium and a supplementary culture medium are adopted for large-scale production and expression of protein drugs, the basic culture medium is suitable for cell amplification and perfusion culture, and the supplementary culture medium is suitable for supplementary batch culture. The protein drug expressed by the method does not contain non-human glycosylation.

The invention discloses an environmental stimulation responsive protein polymer conjugate self-assembled body and a preparation method and application thereof and belongs to the field of biomedicine.A protein polymer conjugate of the self-assembled body comprises a protein substance and two or more environmental stimulation responsive polymers coupled with the protein substance and is subjected to environmental stimulation sensitive responsive self-assembly under the action of temperature, enzymes, pH, light, static electricity, magnetic fields, chemical substances and other environments, a self-assembled body structure of the protein polymer conjugate can significantly improve the stability of drugs and effectively maintain the activity of the drugs, the half-life periods of the drugs are significantly prolonged at the same time, and pharmacokinetic parameters are improved; moreover, the preparation method is simple, condition parameters are easy to control, and the self-assembled body has a high practical value. The environmental stimulation responsive protein polymer conjugate self-assembled body has a broad application prospect in the fields of drug preparation and release control over the drugs.